Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Retrospective study indicates that the age at first testicular cancer diagnosis and treatment intensity influence the second testicular cancer risk
Head to head comparison demonstrates progression-free survival advantage with chemotherapy over palbociclib plus endocrine therapy
Liquid biopsy findings from a prospective Oesophageal Cancer Classification and Molecular Stratification Consortium study
Efficacy of selinexor in combination with bortezomib and dexamethasone was evaluated in the BOSTON study
Efficacy was evaluated in HERO study
Efficacy was demonstrated in ADAURA study
Evidence for efficacy was evaluated in SOPHIA study
JAK inhibitor is intended for the treatment of primary myelofibrosis and of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia
It is intended for the treatment of HER2-positive locally advanced or metastatic breast cancer
It is intended for the treatment of relapsed or refractory hairy cell leukaemia
Sunitinib Accord is a generic of Sutent, which has been authorised in the EU since 2006
New indication concerns the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
